US Stock MarketDetailed Quotes

NTLA Intellia Therapeutics

Watchlist
  • 21.460
  • -0.920-4.11%
Close Aug 9 16:00 ET
  • 21.500
  • +0.040+0.19%
Post 20:02 ET
2.18BMarket Cap-3916P/E (TTM)

Intellia Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
(Q3)Sep 30, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
35.58%-58.19M
-10.37%-120.66M
-18.24%-394.09M
-3.54%-93.05M
-29.11%-101.38M
-6.15%-90.32M
-37.00%-109.33M
-48.11%-333.29M
-64.44%-89.87M
-20.77%-78.53M
Net income from continuing operations
-18.83%-146.98M
-4.18%-107.44M
-1.48%-481.19M
-16.54%-132.16M
-7.94%-122.22M
-22.85%-123.68M
29.79%-103.13M
-77.01%-474.19M
-39.60%-113.41M
-58.04%-113.23M
Operating gains losses
----
----
43.86%15.71M
47.63%4.8M
130.08%3.85M
23.46%4.02M
11.04%3.05M
723.92%10.92M
--3.25M
--1.67M
Depreciation and amortization
19.77%2.6M
22.54%2.51M
18.54%8.98M
21.42%2.47M
17.44%2.29M
18.13%2.17M
16.88%2.05M
9.88%7.57M
8.03%2.03M
9.18%1.95M
Other non cash items
--0
-820.02%-20.97M
-91.69%6.72M
--0
-90.94%968K
6.44%2.84M
-95.08%2.91M
2,653.83%80.88M
--8.3M
--10.68M
Change In working capital
695.46%29.62M
19.43%-29.73M
2.64%-52.45M
123.18%3.11M
-142.66%-13.69M
71.15%-4.98M
-110.02%-36.9M
-135.21%-53.87M
-513.02%-13.42M
55.49%-5.64M
-Change in receivables
16,059.60%24.1M
102.55%29K
-1,781.87%-32.69M
-11,850.98%-29.97M
-22.77%-1.43M
85.67%-151K
-594.78%-1.14M
-1,854.55%-1.74M
-44.57%255K
-134.54%-1.17M
-Change in prepaid assets
298.50%2.51M
-81.64%-8.75M
-1,157.78%-27.17M
-695.13%-15.36M
-765.26%-5.73M
-10,625.00%-1.26M
-1,241.00%-4.82M
77.95%-2.16M
59.11%-1.93M
-118.24%-662K
-Change in payables and accrued expense
-27.93%7.2M
-3.77%-16.83M
-24.64%8.55M
239.43%12.97M
-84.84%1.81M
1,619.63%9.98M
-329.84%-16.22M
-36.25%11.34M
-81.65%3.82M
213.06%11.95M
-Change in other current assets
25.54%5.78M
33.06%5.68M
52.15%18.3M
11.03%4.99M
49.66%4.44M
63.70%4.61M
143.30%4.27M
27.09%12.03M
52.25%4.5M
8.96%2.97M
-Change in other current liabilities
-20.33%-4.57M
-1.43%-4.48M
-68.67%-16.67M
-33.58%-4.46M
-91.29%-4M
-68.46%-3.8M
-100.54%-4.42M
-8.53%-9.88M
-75.62%-3.34M
3.11%-2.09M
-Change in other working capital
62.45%-5.39M
63.15%-5.37M
95.62%-2.78M
308.83%34.93M
47.20%-8.79M
10.87%-14.35M
-4.08%-14.57M
-102.40%-63.46M
-16.40%-16.73M
-186.55%-16.64M
Cash from discontinued investing activities
Operating cash flow
35.58%-58.19M
-10.37%-120.66M
-18.24%-394.09M
-3.54%-93.05M
-29.11%-101.38M
-6.15%-90.32M
-37.00%-109.33M
-48.11%-333.29M
-64.44%-89.87M
-20.77%-78.53M
Investing cash flow
Cash flow from continuing investing activities
29.96%-24.19M
104.83%5.9M
-119.55%-31.35M
252.36%45.94M
66.87%79.5M
-136.22%-34.54M
-357.51%-122.25M
129.11%160.31M
81.05%-30.15M
111.93%47.64M
Net PPE purchase and sale
76.47%-1.01M
34.60%-2.51M
-4.30%-13.99M
61.15%-1.52M
-5.99%-4.33M
-8.07%-4.3M
-168.16%-3.83M
-5.11%-13.41M
-36.40%-3.91M
9.94%-4.09M
Net intangibles purchase and sale
----
----
--0
--0
----
----
----
---44.83M
--0
--0
Net business purchase and sale
----
----
--0
----
----
----
----
--0
----
----
Net investment purchase and sale
23.35%-23.18M
107.10%8.41M
-107.94%-17.36M
280.87%47.46M
62.06%83.83M
-130.44%-30.24M
-226.33%-118.42M
140.85%218.55M
82.88%-26.24M
113.10%51.73M
Cash from discontinued investing activities
Investing cash flow
29.96%-24.19M
104.83%5.9M
-119.55%-31.35M
252.36%45.94M
66.87%79.5M
-136.22%-34.54M
-357.51%-122.25M
129.11%160.31M
81.05%-30.15M
111.93%47.64M
Financing cash flow
Cash flow from continuing financing activities
1,539.35%41.25M
2,601.13%59.99M
-77.64%130.32M
-78.95%106.48M
-20.33%19.1M
-57.32%2.52M
-95.31%2.22M
-20.87%582.96M
22,082.59%505.76M
-96.41%23.98M
Net common stock issuance
--38.4M
3,858.66%58.03M
-78.83%119.8M
-79.43%103.61M
-36.71%14.72M
--0
-96.23%1.47M
-18.42%565.79M
--503.65M
-96.41%23.26M
Proceeds from stock option exercised by employees
13.20%2.85M
159.34%1.96M
-38.67%10.53M
35.90%2.87M
507.20%4.38M
-57.32%2.52M
-91.05%755K
-60.19%17.17M
-7.28%2.11M
-96.45%722K
Cash from discontinued financing activities
Financing cash flow
1,539.35%41.25M
2,601.13%59.99M
-77.64%130.32M
-78.95%106.48M
-20.33%19.1M
-57.32%2.52M
-95.31%2.22M
-20.87%582.96M
22,082.59%505.76M
-96.41%23.98M
Net cash flow
Beginning cash position
-39.37%185.58M
-55.11%240.35M
326.71%535.46M
20.88%180.98M
17.33%183.76M
117.90%306.11M
326.71%535.46M
-23.77%125.49M
-55.57%149.72M
18.04%156.63M
Current changes in cash
66.38%-41.13M
76.12%-54.77M
-171.98%-295.11M
-84.61%59.37M
59.76%-2.78M
-857.60%-122.35M
-1,629.85%-229.36M
1,148.00%409.98M
282.40%385.74M
-103.38%-6.91M
End cash Position
-21.39%144.45M
-39.37%185.58M
-55.11%240.35M
-55.11%240.35M
20.88%180.98M
17.33%183.76M
117.90%306.11M
326.71%535.46M
326.71%535.46M
-55.57%149.72M
Free cash flow
37.44%-59.2M
-8.84%-123.17M
-4.19%-408.07M
-0.85%-94.57M
-27.73%-105.71M
-6.23%-94.62M
10.23%-113.16M
-64.72%-391.68M
-63.04%-93.78M
-18.98%-82.76M
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022(Q3)Sep 30, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities 35.58%-58.19M-10.37%-120.66M-18.24%-394.09M-3.54%-93.05M-29.11%-101.38M-6.15%-90.32M-37.00%-109.33M-48.11%-333.29M-64.44%-89.87M-20.77%-78.53M
Net income from continuing operations -18.83%-146.98M-4.18%-107.44M-1.48%-481.19M-16.54%-132.16M-7.94%-122.22M-22.85%-123.68M29.79%-103.13M-77.01%-474.19M-39.60%-113.41M-58.04%-113.23M
Operating gains losses --------43.86%15.71M47.63%4.8M130.08%3.85M23.46%4.02M11.04%3.05M723.92%10.92M--3.25M--1.67M
Depreciation and amortization 19.77%2.6M22.54%2.51M18.54%8.98M21.42%2.47M17.44%2.29M18.13%2.17M16.88%2.05M9.88%7.57M8.03%2.03M9.18%1.95M
Other non cash items --0-820.02%-20.97M-91.69%6.72M--0-90.94%968K6.44%2.84M-95.08%2.91M2,653.83%80.88M--8.3M--10.68M
Change In working capital 695.46%29.62M19.43%-29.73M2.64%-52.45M123.18%3.11M-142.66%-13.69M71.15%-4.98M-110.02%-36.9M-135.21%-53.87M-513.02%-13.42M55.49%-5.64M
-Change in receivables 16,059.60%24.1M102.55%29K-1,781.87%-32.69M-11,850.98%-29.97M-22.77%-1.43M85.67%-151K-594.78%-1.14M-1,854.55%-1.74M-44.57%255K-134.54%-1.17M
-Change in prepaid assets 298.50%2.51M-81.64%-8.75M-1,157.78%-27.17M-695.13%-15.36M-765.26%-5.73M-10,625.00%-1.26M-1,241.00%-4.82M77.95%-2.16M59.11%-1.93M-118.24%-662K
-Change in payables and accrued expense -27.93%7.2M-3.77%-16.83M-24.64%8.55M239.43%12.97M-84.84%1.81M1,619.63%9.98M-329.84%-16.22M-36.25%11.34M-81.65%3.82M213.06%11.95M
-Change in other current assets 25.54%5.78M33.06%5.68M52.15%18.3M11.03%4.99M49.66%4.44M63.70%4.61M143.30%4.27M27.09%12.03M52.25%4.5M8.96%2.97M
-Change in other current liabilities -20.33%-4.57M-1.43%-4.48M-68.67%-16.67M-33.58%-4.46M-91.29%-4M-68.46%-3.8M-100.54%-4.42M-8.53%-9.88M-75.62%-3.34M3.11%-2.09M
-Change in other working capital 62.45%-5.39M63.15%-5.37M95.62%-2.78M308.83%34.93M47.20%-8.79M10.87%-14.35M-4.08%-14.57M-102.40%-63.46M-16.40%-16.73M-186.55%-16.64M
Cash from discontinued investing activities
Operating cash flow 35.58%-58.19M-10.37%-120.66M-18.24%-394.09M-3.54%-93.05M-29.11%-101.38M-6.15%-90.32M-37.00%-109.33M-48.11%-333.29M-64.44%-89.87M-20.77%-78.53M
Investing cash flow
Cash flow from continuing investing activities 29.96%-24.19M104.83%5.9M-119.55%-31.35M252.36%45.94M66.87%79.5M-136.22%-34.54M-357.51%-122.25M129.11%160.31M81.05%-30.15M111.93%47.64M
Net PPE purchase and sale 76.47%-1.01M34.60%-2.51M-4.30%-13.99M61.15%-1.52M-5.99%-4.33M-8.07%-4.3M-168.16%-3.83M-5.11%-13.41M-36.40%-3.91M9.94%-4.09M
Net intangibles purchase and sale ----------0--0---------------44.83M--0--0
Net business purchase and sale ----------0------------------0--------
Net investment purchase and sale 23.35%-23.18M107.10%8.41M-107.94%-17.36M280.87%47.46M62.06%83.83M-130.44%-30.24M-226.33%-118.42M140.85%218.55M82.88%-26.24M113.10%51.73M
Cash from discontinued investing activities
Investing cash flow 29.96%-24.19M104.83%5.9M-119.55%-31.35M252.36%45.94M66.87%79.5M-136.22%-34.54M-357.51%-122.25M129.11%160.31M81.05%-30.15M111.93%47.64M
Financing cash flow
Cash flow from continuing financing activities 1,539.35%41.25M2,601.13%59.99M-77.64%130.32M-78.95%106.48M-20.33%19.1M-57.32%2.52M-95.31%2.22M-20.87%582.96M22,082.59%505.76M-96.41%23.98M
Net common stock issuance --38.4M3,858.66%58.03M-78.83%119.8M-79.43%103.61M-36.71%14.72M--0-96.23%1.47M-18.42%565.79M--503.65M-96.41%23.26M
Proceeds from stock option exercised by employees 13.20%2.85M159.34%1.96M-38.67%10.53M35.90%2.87M507.20%4.38M-57.32%2.52M-91.05%755K-60.19%17.17M-7.28%2.11M-96.45%722K
Cash from discontinued financing activities
Financing cash flow 1,539.35%41.25M2,601.13%59.99M-77.64%130.32M-78.95%106.48M-20.33%19.1M-57.32%2.52M-95.31%2.22M-20.87%582.96M22,082.59%505.76M-96.41%23.98M
Net cash flow
Beginning cash position -39.37%185.58M-55.11%240.35M326.71%535.46M20.88%180.98M17.33%183.76M117.90%306.11M326.71%535.46M-23.77%125.49M-55.57%149.72M18.04%156.63M
Current changes in cash 66.38%-41.13M76.12%-54.77M-171.98%-295.11M-84.61%59.37M59.76%-2.78M-857.60%-122.35M-1,629.85%-229.36M1,148.00%409.98M282.40%385.74M-103.38%-6.91M
End cash Position -21.39%144.45M-39.37%185.58M-55.11%240.35M-55.11%240.35M20.88%180.98M17.33%183.76M117.90%306.11M326.71%535.46M326.71%535.46M-55.57%149.72M
Free cash flow 37.44%-59.2M-8.84%-123.17M-4.19%-408.07M-0.85%-94.57M-27.73%-105.71M-6.23%-94.62M10.23%-113.16M-64.72%-391.68M-63.04%-93.78M-18.98%-82.76M
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ----Unqualified Opinion--------Unqualified Opinion----

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg
Concept ARK Portfolio
ARK Portfolio
Intraday+0.84%
Gene Editing
Gene Editing
Intraday+0.23%